RecruitingPhase 3NCT05331521
A Clinical Study to Improve Brain Function and Quality of Life of Patients With Newly Diagnosed Brain Tumors (Gliomas).
Studying Oligodendroglioma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University Hospital Heidelberg
- Principal Investigator
- Wolfgang Wick, Prof. Dr.University Hospital Heidelberg
- Intervention
- CETEG(drug)
- Enrollment
- 406 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2021 – 2033
Study locations (19)
- University Hospital Heidelberg, Department of Neurooncology, Heidelberg, Baden-Wurttemberg, Germany
- Charité, University Medicine Berlin, Neurosurgery, Berlin, Germany
- Knappschaftskrankenhaus Bochum GmbH, Neurology Clinic, Bochum, Germany
- University Hospital Bonn, Neurology Clinic, Bonn, Germany
- Chemnitz Hospital, Neurosurgery, Chemnitz, Germany
- University Hospital Cologne, Neurosurgery, Cologne, Germany
- University Hospital Duesseldorf, Neurooncology, Düsseldorf, Germany
- University Hospital Frankfurt, Neurooncology, Frankfurt, Germany
- University Hospital Göttingen, Neurosurgery, Göttingen, Germany
- University Hospital Saarland, Neurosurgery, Homburg, Germany
- University Hospital of Jena, Neurosurgery, Jena, Germany
- University Hospital Leipzig, Radiation Therapy, Leipzig, Germany
- University Hospital Mannheim, Neurology Clinic, Mannheim, Germany
- University Clinic Muehlenkreis, Minden, Minden, Germany
- University Hospital rechts der Isar, Radiation Oncology, Munich, Germany
- +4 more locations on ClinicalTrials.gov
Collaborators
Universitätsmedizin Mannheim · Ruhr University of Bochum
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05331521 on ClinicalTrials.govOther trials for Oligodendroglioma
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT06989086FearLess in NeuroOncologyVirginia Commonwealth University
- ACTIVE NOT RECRUITINGPHASE1NCT06254326ADAGiO: Adoptive Cellular Therapy for the TreAtment of Recurrent OliGodendrogliOma (OG) Adult PatientsUniversity of Florida
- RECRUITINGPHASE2NCT05512351Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNAlevel- Relapse and Clinical-relapse OligodendrogliomaHenan Provincial People's Hospital
- RECRUITINGNANCT05190172PRO-GLIO: PROton Versus Photon Therapy in IDH-mutated Diffuse Grade II and III GLIOmasOslo University Hospital
- RECRUITINGPHASE3NCT04702581A Randomized Trial of Delayed Radiotherapy in Patients Low-grade Oligodendrogliomas Requiring a Treatment Other Than SurgeryHospices Civils de Lyon
- ACTIVE NOT RECRUITINGPHASE2NCT03969706Abemaciclib in Patients with OligodendrogliomaStephen Bagley, MD, MSCE